IDH1 and acute myeloid leukemia: IDH1/IDH2 mutations are detected in about 10% of AML cases but, differently from diffuse gliomas, the prognostic role of this molecular hallmark is controversial in this different neoplasm, although it represents an effective therapeutic target [4].